As aberrant PTEN subcellular localization, including loss of nuclear PTEN, is often observed in human cancer [6,7,8], further studies are needed to determine whether PTEN nuclear-excluded mutant cancer cells are susceptible to cell killing by antifolate drugs in vitro and in vivo. This evidence concerns the gene PTEN and cancer.